Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 17/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671385 | 1.00 | SLC40A1 (0.62) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL4761648 | 1.00 | SLC40A1 (0.62) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL7074716 | 0.94 | SLC40A1 (0.63) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| Bromide SCHEMBL7074322 | 0.93 | SLC40A1 (0.62) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL31257251 | 0.90 | SLC40A1 (0.59) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL4760828 | 0.90 | SLC40A1 (0.59) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL3370850 | 0.90 | SLC40A1 (0.59) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL7074653 | 0.87 | SLC40A1 (0.49) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL5106464 | 0.86 | SLC40A1 (0.57) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL5112746 | 0.84 | CXCR4 (0.52) | SLC40A1CXCR4CHRM2CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | SLC40A1 2231/4885CXCR4 2/4885CHRM2 2757/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | SLC40A1 2231/4885CXCR4 2/4885CHRM2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.